Sildenafil citrate therapy for severe early-onset intrauterine growth restriction

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 118, Issue 5, 2011, Pages 624-628

  Von Dadelszen, P ^a,b   Dwinnell, S ^a   Magee, L A ^a,b   Carleton, B C ^a,b   Gruslin, A ^c   Lee, B ^a   Lim, K I ^a,b   Liston, R M ^a,b   Miller, S P ^a,b   Rurak, D ^a,b   Sherlock, R L ^a,b   Skoll, M A ^a,b   Wareing, M M ^d   Baker, P N ^e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Case control study; In utero therapy; Intrauterine growth restriction; Maternal outcomes; Perinatal outcomes

Indexed keywords

SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FETUS WEIGHT; GESTATIONAL AGE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MYOMETRIUM; PERINATAL PERIOD; PREGNANCY COMPLICATION; PRIORITY JOURNAL; TREATMENT RESPONSE; VASODILATATION;

ADULT; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; PERINATAL MORTALITY; PIPERAZINES; PLACENTA; PREGNANCY; PREGNANCY OUTCOME; PURINES; SULFONES; UTERUS; VASODILATOR AGENTS;

EID: 79952652279     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2010.02879.x     Document Type: Article

References (8)

1. Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol 2004;23:119-25. (Pubitemid 38221783)
2. Petersen SG, Wong SF, Urs P, Gray PH, Gardener GJ. Early onset, severe fetal growth restriction with absent or reversed enddiastolic flow velocity waveform in the umbilical artery: perinatal and long-term outcomes. Aust NZ J Obstet Gynaecol 2009;49:45-51.
3. Wareing M, Myers JE, O'Hara M, Baker PN. Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. J Clin Endocrinol Metab 2005;90:2550-5. (Pubitemid 40686290)
4. Lessoway VA, Schulzer M, Wittmann BK, Gagnon FA, Wilson RD. Ultrasound fetal biometry charts for a North American Caucasian population. J Clin Ultrasound 1998;26:433-53. (Pubitemid 28481835)
5. von DadelszenP, Magee LA, Lee SK, Stewart SD, Simone C, Koren G, et al. Activated protein C in normal human pregnancy and pregnancies complicated by severe preeclampsia: a therapeutic opportunity? Crit Care Med 2002;30:1883-92.
6. Gulmezoglu AM, Hofmeyr GJ. Calcium channel blockers for potential impaired fetal growth. Cochrane Database Syst Rev 2000;2: CD000049.
7. Winer N, Branger B, Azria E, Tsatsaris V, Philippe HJ, Roze JC, et al. L-Arginine treatment for severe vascular fetal intrauterine growth restriction: a randomized double-bind controlled trial. Clin Nutr 2009;28:243-8.
8. Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of pre-eclampsia. Hypertens Pregnancy 2009;28:369-82.